Intraperitoneal Immunotherapy to Prevent Peritoneal Carcinomatosis in Patients with Advanced Gastrointestinal Malignancies

Overview

Journal J Surg Oncol

Specialties General Surgery
Oncology

Date 2009 Aug 22

PMID 19697440

Citations 4

Authors

Michael A Strohlein

Markus M Heiss

Affiliations

Soon will be listed here.

Abstract

Prognosis of peritoneal carcinomatosis (PC) from GI tract cancers remains poor. As 30% of patients develop PC after curative surgery, prevention of PC during cancer resection would be desirable. Regarding physiopathology of PC and intraperitoneal immunology, intraoperative application of trifunctional antibodies offers advanced opportunities for destruction of intraperitoneal tumor cells and prevention of PC. First results indicated, the intraoperative treatment with trifunctional antibodies was safe and clinically feasible. Long-term results will be available in 2010.

Citing Articles

Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes.

Cyrelle Ornella M, Badrinath N, Kim K, Kim J, Cho E, Hwang T Cancers (Basel). 2023; 15(8).

PMID: 37190310 PMC: 10137063. DOI: 10.3390/cancers15082383.

Multidisciplinary Treatment for Colorectal Peritoneal Metastases: Review of the Literature.

Mo S, Cai G Gastroenterol Res Pract. 2017; 2016:1516259.

PMID: 28105045 PMC: 5220469. DOI: 10.1155/2016/1516259.

Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.

Sangisetty S, Miner T World J Gastrointest Surg. 2012; 4(4):87-95.

PMID: 22590662 PMC: 3351493. DOI: 10.4240/wjgs.v4.i4.87.

Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.

Mundy-Bosse B, Young G, Bauer T, Binkley E, Bloomston M, Bill M Cancer Immunol Immunother. 2011; 60(9):1269-79.

PMID: 21604071 PMC: 3521517. DOI: 10.1007/s00262-011-1029-z.